Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus:

Elsayed Z Soliman1, Robert P Byington2, J Thomas Bigger2

  • 1From the Division of Public Health Sciences, Epidemiological Cardiology Research Center (EPICARE) (E.Z.S.); Section of Cardiology, Department of Medicine (E.Z.S.), Division of Public Health Sciences, Department of Epidemiology (E.Z.S., R.P.B), and Division of Public Health Sciences, Department of Biostatistical Sciences (G.E., H.C.), Wake Forest School of Medicine, Winston-Salem, NC; Division of Cardiology, Department of Medicine, Columbia University, New York, NY (J.T.B.); Division of Cardiology, Department of Medicine, Weill Cornell Medical College, New York, NY (P.M.O.); and Colorado School of Public Health, Aurora (D.C.G.). esoliman@wakehealth.edu.

Insights

Intensive blood pressure lowering to below 120 mm Hg significantly reduced left ventricular hypertrophy (LVH) risk in patients with diabetes. This strategy promoted LVH regression and prevented new cases, offering greater cardiac protection than standard lowering to below 140 mm Hg.

Area of Science:

  • Cardiology
  • Hypertension Management
  • Diabetology

Background:

  • Left ventricular hypertrophy (LVH) is a key indicator of cardiac damage in hypertension.
  • Regression of LVH is possible with sustained blood pressure (BP) reduction.
  • The impact of intensive BP lowering on LVH risk in diabetic patients remains unclear.

Purpose of the Study:

  • To investigate whether a BP-lowering strategy targeting systolic BP <120 mm Hg reduces LVH risk compared to a standard strategy (systolic BP <140 mm Hg).
  • To assess the effect of intensive BP lowering on LVH regression and incidence in patients with diabetes mellitus.

Main Methods:

  • Analysis of 4331 patients with diabetes from the ACCORD BP trial, a randomized controlled trial.
  • Comparison of intensive (systolic BP <120 mm Hg) versus standard (systolic BP <140 mm Hg) BP-lowering arms.
  • Electrocardiographic LVH assessment using Cornell voltage (binary) and Cornell index (continuous) at baseline and after median 4.4-year follow-up.

Main Results:

  • Intensive BP lowering was associated with a 39% lower risk of LVH (OR 0.61; P=0.008).
  • The adjusted mean Cornell index was significantly lower in the intensive arm (1352 vs. 1447 µV; P<0.001).
  • Intensive BP lowering led to greater LVH regression and a lower incidence of new LVH.

Conclusions:

  • Targeting a systolic BP <120 mm Hg, compared to <140 mm Hg, significantly reduces LVH risk in hypertensive patients with diabetes.
  • Intensive BP lowering promotes LVH regression and prevents new LVH development.
  • This strategy offers superior cardiac protection in this high-risk population.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
532
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.8K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718